Losartan in Prevention of Radiation-Induced Heart Failure

• Status: Not yet recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study is being done to see if losartan affects the chances of developing radiation-induced heart failure in patients who are receiving radiation therapy as part of standard of care treatment for breast cancer.

The interventions involved in this study are:

• Losartan

• Radiation Therapy (standard of care)

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Treatments: Losartan

Criteria

Inclusion Criteria:

->18 years of age

• Non-metastatic Breast Cancer patients who are scheduled to receive conventional left breast/chest wall RT inclusive of treatment to the internal mammary lymph nodes (IMNs)

• Prior chemotherapy is permitted

• Patients must have Left-sided Breast Cancer

• Ability to understand and the willingness to sign a written informed consent document

• No contraindication to MRI

Exclusion Criteria:

• Person who is pregnant or breastfeeding.

• Patient unable to swallow oral medication.

• Patients receiving any other investigational agent will not be excluded from study eligibility, unless the patient is already enrolled in an interventional study evaluating cardiac toxicity

• Patients already receiving ACE/ARBs.

• Patients with a history of allergic reactions to Losartan biosimilars.